Back to Agenda
Session 2: An In-Depth Look at ISPY2
Session Chair(s)
Scott Berry, PhD
President and Senior Statistical Scientist, Berry Consultants LLC, United States
Daniel Millar, MBA
Senior Director, Strategic Business Transformation, Johnson & Johnson, United States
Get and in-depth look at ISPY2, an exploratory-phase platform trial designed to investigate new treatments for biomarker-identified subtypes of early-stage breast cancer in the context of neoadjuvant therapy.
Speaker(s)
Donald A Berry, PhD
Professor, Department of Biostatistics, M.D. Anderson Cancer Center, United States
An In-Depth Look at I-SPY 2
Have an account?